Several possible studies
Story checked
The Coronary Artery Inflammation Controversy (opens in a new tab)
substack.com · 2026-09-05
Short answer
Several possible studiesNo clear answer.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
The Coronary Artery Inflammation Controversy
substack.com · 2026-09-05
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
Several studies could be the source of this story.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Open claim evidenceSearch result
Several studies could fit.
More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.
Source layer
The 5 papers the story cites
Source study separated from background citations.
The research anchor for the report.
- Cited as backgroundpresented as earlier work
Prevalence of Silent Atherosclerosis across Adult Life
New England Journal of Medicine · 2026
- Cited as backgroundpresented as earlier work
High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound.
Circulation · 2001
- Cited as backgroundpresented as earlier work
The genetics of heart attack.
Heart (British Cardiac Society) · 2006
- Cited as backgroundpresented as earlier work
Atherosclerosis — An Inflammatory Disease
New England Journal of Medicine · 1999
- Cited as backgroundpresented as earlier work
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
JACC · 2026
Evidence layer
Claim by claim
What the story asserts. With no source study, there is nothing to check these against.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 7Not checkedA large ziltivekimab (ZEUS) trial in more than 6,300 participants lowered IL-6 and hs-CRP but did not reduce cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.View evidenceHide evidence
As statedMore than 6,300 participants; biomarkers markedly reduced; no reduction in major cardiovascular events
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 2 of 7Not checkedThe article says the ZEUS failure should not be taken to mean the inflammation hypothesis is wrong; instead, it suggests the problem may be the target, the population, or the lack of evidence that participants had coronary artery inflammation.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 3 of 7Not checkedFor the Lp(a) story, the article says the HORIZON pelacarsen outcome trial was a randomized, double-blind multinational trial of more than 8,300 participants, and that it failed to reduce cardiovascular events.View evidenceHide evidence
As statedMore than 8,300 participants; over 900 sites; no outcome benefit
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 4 of 7Not checkedIt argues that hs-CRP and IL-6 are nonspecific blood markers and do not reliably indicate inflammation in the coronary arteries.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 5 of 7Not checkedThe article says coronary artery inflammation can be measured noninvasively using AI analysis of epicardial fat attenuation index (FAI) on coronary CT angiography, and that this approach has been validated in large Oxford datasets.View evidenceHide evidence
As statedValidated in 40,000 consecutive CT angiograms; later data from more than 19,000 patients
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 6 of 7Not checkedThe piece suggests the HORIZON failure may reflect Lp(a) being an imperfect marker of pathogenicity, since its pro-inflammatory potential depends partly on oxidized phospholipid cargo that is not measured clinically.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Claim 7 of 7Not checkedThe article argues that future anti-inflammatory or lipid trials should enroll patients with confirmed coronary inflammation rather than relying only on elevated blood biomarkers or kidney-disease populations.View evidenceHide evidence
Not checked
NewsLink could not identify one source study, so this claim was not compared against a paper.
Method layer
No single source study was found.
NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.
Nearby research
No exact source, but these papers are close.
Crossref, PubMed, Europe PMC · 20 candidate papers
Prevalence of Silent Atherosclerosis across Adult Life
New England Journal of Medicine · 2026 · Crossref
High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound.
Circulation · 2001 · PubMed
The genetics of heart attack.
Heart (British Cardiac Society) · 2006 · PubMed
Atherosclerosis — An Inflammatory Disease
New England Journal of Medicine · 1999 · Crossref
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
JACC · 2026 · Crossref
And 15 more candidates considered.